ACADIA PharmaceuticalsMEX:ACAD 73 PS Ratio is 3.09 as of Jul. 01, 2026, which is 64% below its 10-year median of 8.49. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.85 (Fairly Valued). The stock has 9 warning signs investors should review. Among 934 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 71.73% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ACADIA Pharmaceuticals's share price is MXN362.00.
ACADIA Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN117.17. Hence, ACADIA Pharmaceuticals's PS Ratio for today is 3.09.
The historical rank and industry rank for ACADIA Pharmaceuticals's PS Ratio or its related term are showing as below:
MEX:ACAD'
s PS Ratio Range Over the Past 10 Years
Min: 2.44 Med: 8.49 Max: 37040
Current: 3.95
During the past 13 years, ACADIA Pharmaceuticals's highest PS Ratio was 37040.00. The lowest was 2.44. And the median was 8.49.
MEX:ACAD's PS Ratio is ranked better than 71.73% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs MEX:ACAD: 3.95
ACADIA Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of ACADIA Pharmaceuticals was 7.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 25.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 79.30% per year.
During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 1109.20% per year. The lowest was -77.60% per year. And the median was -2.40% per year.
Back to Basics: PS Ratio
ACADIA Pharmaceuticals (MEX:ACAD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ACADIA Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ACADIA Pharmaceuticals's Share Price of today is MXN362.00. ACADIA Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN117.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ACADIA Pharmaceuticals (MEX:ACAD) has a PS Ratio of 3.09 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ACADIA Pharmaceuticals and its competitors. This is 64% below median its historical median of 8.49. Over the past decade, ACADIA Pharmaceuticals' PS Ratio has ranged from 2.44 to 37,040.00. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #264 out of 934 companies in the Biotechnology industry, placing it in the top 28.3%.
Is ACADIA Pharmaceuticals' PS Ratio too high?
ACADIA Pharmaceuticals' current PS Ratio of 3.09 is 64% below median its 10-year median of 8.49. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 37,040.00. The Biotechnology industry median PS Ratio is 9.52. ACADIA Pharmaceuticals' value of 3.09 is 67.5% below this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #264 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' PS Ratio compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #264 out of 934 companies for PS Ratio. This puts ACADIA Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.52. ACADIA Pharmaceuticals' value of 3.09 is 67.5% below this benchmark. Historically, ACADIA Pharmaceuticals' own PS Ratio has ranged from 2.44 to 37,040.00 over the past decade. While the company's 10-year median is 8.49 vs. the industry median of 9.52, ACADIA Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current PS Ratio of 3.09 is 67.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current PS Ratio is 3.09, which is 64% below median its own 10-year median of 8.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.85, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current PS Ratio is 3.09, which is 64% below median its 10-year median of 8.49 and 67.5% below the Biotechnology industry median of 9.52. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current PS Ratio is 3.09 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.85.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
PS Ratio: 3.09 (64% below median its 10-year median of 8.49)
GF Value™: MXN357.85 vs. price of MXN362.00 (1.2% above fair value)
Industry Position: 67.5% below the Biotechnology median (#264 of 934)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
